<?xml version="1.0" encoding="UTF-8"?><xml><records><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Andika Perdani Somawi</style></author><author><style face="normal" font="default" size="100%">Nancy Margarita Rehatta</style></author><author><style face="normal" font="default" size="100%">Prihatma Kriswidyatomo</style></author><author><style face="normal" font="default" size="100%">Kohar Hari Santoso</style></author><author><style face="normal" font="default" size="100%">Hamzah</style></author><author><style face="normal" font="default" size="100%">Pudji Lestari</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Effect of Propofol TIVA Compared Sevoflurane Inhalation Anesthesia on Triglyceride Levels After Elective Craniotomy Surgery</style></title><secondary-title><style face="normal" font="default" size="100%">Pharmacognosy Journal</style></secondary-title></titles><keywords><keyword><style  face="normal" font="default" size="100%">Craniotomy</style></keyword><keyword><style  face="normal" font="default" size="100%">Sevoflurane</style></keyword><keyword><style  face="normal" font="default" size="100%">TIVA propofol</style></keyword><keyword><style  face="normal" font="default" size="100%">Triglycerides</style></keyword></keywords><dates><year><style  face="normal" font="default" size="100%">2024</style></year><pub-dates><date><style  face="normal" font="default" size="100%">June 2024</style></date></pub-dates></dates><volume><style face="normal" font="default" size="100%">16</style></volume><pages><style face="normal" font="default" size="100%">597-601</style></pages><language><style face="normal" font="default" size="100%">eng</style></language><abstract><style face="normal" font="default" size="100%">&lt;p class=&quot;rtejustify&quot;&gt;&lt;strong&gt;Background:&lt;/strong&gt; Propofol TIVA has been shown to be more effective than sevoflurane in craniotomy surgery. Propofol TIVA offers the benefit of giving better brain relaxation during surgery while also being less expensive than sevoflurane. Nonetheless, it is important to highlight that propofol has side effects that should be considered. Large doses and prolonged anesthesia may result in increased triglycerides (lipids) as well as Propofol Infusion Syndrome (PRIS). As part of their investigation into the detrimental effects of propofol, researchers discovered the necessity for controls to avoid confusing the effects of the surgery itself. Therefore, sevoflurane was chosen as the control group to comprehend and analyze the effects of propofol more accurately. &lt;strong&gt;Methods: &lt;/strong&gt;A prospective observational study analysis was conducted on elective craniotomy patients at RSUD Dr. Soetomo from November to December 2023. 52 subjects were divided into two groups, namely the TIVA Propofol and Sevoflurane Inhalation groups. Each group will be examined for preoperative triglyceride levels and postoperative triglyceride levels while already in the ICU. &lt;strong&gt;Results:&lt;/strong&gt; Postoperative triglyceride levels in the Propofol TIVA group were significantly higher. In the comparison test between the two anesthesia methods on triglyceride levels, there was a significant effect in the Propofol TIVA group. In the test of the relationship between the duration of anesthesia in both groups, there was no significant relationship. In the test of the relationship between the total dose of propofol and triglyceride levels, it was found that the greater the dose of propofol used, the higher the increase in triglyceride levels. In the test of the relationship between the total amount of sevoflurane and triglyceride levels, it was found that the greater the dose of sevoflurane used, the greater the decrease in triglyceride levels, which was statistically not significant.&lt;strong&gt; Conclusion:&lt;/strong&gt; TIVA Propofol increases triglyceride levels compared to sevoflurane inhalation in patients undergoing elective craniotomies.&lt;/p&gt;
</style></abstract><issue><style face="normal" font="default" size="100%">3</style></issue><work-type><style face="normal" font="default" size="100%">Research Article</style></work-type><section><style face="normal" font="default" size="100%">597</style></section><auth-address><style face="normal" font="default" size="100%">&lt;p&gt;&lt;strong&gt;Andika Perdani Somawi&lt;sup&gt;1&lt;/sup&gt;*, Nancy Margarita Rehatta&lt;sup&gt;1&lt;/sup&gt;, Prihatma Kriswidyatomo&lt;sup&gt;1&lt;/sup&gt;, Kohar Hari Santoso&lt;sup&gt;1&lt;/sup&gt;, Hamzah&lt;sup&gt;1&lt;/sup&gt;, Pudji Lestari&lt;sup&gt;2&lt;/sup&gt;&lt;/strong&gt;&lt;/p&gt;

&lt;p&gt;&lt;sup&gt;1&lt;/sup&gt;Departement of Anesthesiology and Reanimation, Faculty of Medicine, Universitas Airlangga, Dr. Soetomo General Academic Hospital, Surabaya, East Java, INDONESIA.&lt;/p&gt;

&lt;p&gt;&lt;sup&gt;2&lt;/sup&gt;Departement of Public Health Science Preventive Medicine, Faculty of Medicine, Universitas Airlangga, Surabaya, East Java, INDONESIA.&lt;/p&gt;
</style></auth-address></record><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Herry Cahya Fathani</style></author><author><style face="normal" font="default" size="100%">Herdiani Sulistyo Putri</style></author><author><style face="normal" font="default" size="100%">Prananda Surya Airlangga</style></author><author><style face="normal" font="default" size="100%">Christrijogo Sumartono Waloejo</style></author><author><style face="normal" font="default" size="100%">Ira Sari Yudaniayanti</style></author><author><style face="normal" font="default" size="100%">Pudji Lestari</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Effective Dose of Cocoa as a Preemptive Analgesic and Anti- Inflammatory Agent Assessed through Pain Scale and Tumor Necrosis Factor Alpha (TNF-α) in an Acute Pain Animal Model</style></title><secondary-title><style face="normal" font="default" size="100%">Pharmacognosy Journal</style></secondary-title></titles><keywords><keyword><style  face="normal" font="default" size="100%">Cocoa</style></keyword><keyword><style  face="normal" font="default" size="100%">Pain</style></keyword><keyword><style  face="normal" font="default" size="100%">Pain Degree Analgesia</style></keyword><keyword><style  face="normal" font="default" size="100%">TNF-α</style></keyword></keywords><dates><year><style  face="normal" font="default" size="100%">2024</style></year><pub-dates><date><style  face="normal" font="default" size="100%">October 2024</style></date></pub-dates></dates><volume><style face="normal" font="default" size="100%">16</style></volume><pages><style face="normal" font="default" size="100%">1134-1137</style></pages><language><style face="normal" font="default" size="100%">eng</style></language><abstract><style face="normal" font="default" size="100%">&lt;p class=&quot;rtejustify&quot;&gt;&lt;strong&gt;Background: &lt;/strong&gt;Pain is a significant issue for 40-50% of hospital patients, with 10-50% of acute pain cases potentially progressing to chronic pain. Pain-associated inflammation often involves the release of mediators, including Tumor Necrosis Factor Alpha (TNF-&lt;strong&gt;α&lt;/strong&gt;). Cocoa beans contain polyphenols, catechins, anthocyanidins, and proanthocyanidins, compounds believed to possess analgesic properties. This study aims to assess cocoa's potential as an oral preemptive analgesic agent in an acute pain mouse model, with an emphasis on its impact on inflammation through TNF-&lt;strong&gt;α&lt;/strong&gt; levels.&lt;strong&gt; Methods: &lt;/strong&gt;This true experimental study involved 24 male white mice split into four groups: a control group (K0) receiving a placebo, a treatment group receiving 15 mg/kg BW oral paracetamol (Kpct), a treatment group receiving 0.5 mg/g BW cocoa (K1), and a treatment group receiving 1 mg/g BW cocoa (K2). Pain response was measured using TNF-&lt;strong&gt;α&lt;/strong&gt; levels and the von Frey test. The Kruskal-Wallis test and One-Way ANOVA were employed for statistical analysis. &lt;strong&gt;Results: &lt;/strong&gt;Cocoa at doses of 0.5 mg/g BW and 1 mg/g BW substantially reduced TNF-&lt;strong&gt;α&lt;/strong&gt; levels (75.82 ± 7.77 and 70.79 ± 11.50, respectively) compared to the control and paracetamol groups (98.22 ± 14.74 and 92.81 ± 2.64). On the first day, compared to the control group's 1.82 ± 0.78 von Frey values, the cocoa-treated groups' values (6.20 ± 2.72 and 7.63 ± 4.11) were notably higher. There were no notable variations in von Frey values across the groups on the second day. However, a correlation was found between von Frey values on the first and second days. &lt;strong&gt;Conclusion:&lt;/strong&gt; Cocoa can potentially serve as an effective preemptive analgesic agent, reducing pain and inflammation primarily by reducing TNF-&lt;strong&gt;α&lt;/strong&gt; levels. These results provide validity to the use of cocoa as an alternative therapy in acute pain management.&lt;/p&gt;
</style></abstract><issue><style face="normal" font="default" size="100%">5</style></issue><work-type><style face="normal" font="default" size="100%">Research Article</style></work-type><section><style face="normal" font="default" size="100%">1134</style></section><auth-address><style face="normal" font="default" size="100%">&lt;p class=&quot;rtejustify&quot;&gt;&lt;strong&gt;Herry Cahya Fathani&lt;sup&gt;1,2&lt;/sup&gt;, Herdiani Sulistyo Putri&lt;sup&gt;1,2*&lt;/sup&gt;, Prananda Surya Airlangga&lt;sup&gt;1,2&lt;/sup&gt;, Christrijogo Sumartono Waloejo&lt;sup&gt;1,2&lt;/sup&gt;, Ira Sari Yudaniayanti&lt;sup&gt;3&lt;/sup&gt;, Pudji Lestari&lt;sup&gt;4&lt;/sup&gt;&lt;/strong&gt;&lt;/p&gt;

&lt;p class=&quot;rtejustify&quot;&gt;&lt;sup&gt;1&lt;/sup&gt;Department of Anesthesiology and Intensive Care, Dr. Soetomo General Academic Hospital, Surabaya, INDONESIA.&lt;/p&gt;

&lt;p class=&quot;rtejustify&quot;&gt;&lt;sup&gt;2&lt;/sup&gt;Department of Anesthesiology and Intensive Care, Faculty of Medicine, Universitas Airlangga, Surabaya, INDONESIA.&lt;/p&gt;

&lt;p class=&quot;rtejustify&quot;&gt;&lt;sup&gt;3&lt;/sup&gt;Department of Clinical Veterinary Medicine, Faculty of Veterinary Medicine, Universitas Airlangga, Surabaya, INDONESIA.&lt;/p&gt;

&lt;p class=&quot;rtejustify&quot;&gt;&lt;sup&gt;4&lt;/sup&gt;Department of Public Health and Preventive Medicine, Faculty of Medicine, Universitas Airlangga, Surabaya, INDONESIA.&lt;/p&gt;
</style></auth-address></record><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Dian Mayangsari</style></author><author><style face="normal" font="default" size="100%">Lukisiari Agustini</style></author><author><style face="normal" font="default" size="100%">Susy Fatmariyanti</style></author><author><style face="normal" font="default" size="100%">Ridholia</style></author><author><style face="normal" font="default" size="100%">Pudji Lestari</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Expression of Matrix Metalloproteinase-9, Transforming Growth Factor Beta and Fibroblast in The Simblefaron Due to Alkali Burn: Literature Review</style></title><secondary-title><style face="normal" font="default" size="100%">Pharmacognosy Journal</style></secondary-title></titles><keywords><keyword><style  face="normal" font="default" size="100%">Alkali</style></keyword><keyword><style  face="normal" font="default" size="100%">Burn</style></keyword><keyword><style  face="normal" font="default" size="100%">Conjunctiva</style></keyword><keyword><style  face="normal" font="default" size="100%">Symblepharon</style></keyword></keywords><dates><year><style  face="normal" font="default" size="100%">2024</style></year><pub-dates><date><style  face="normal" font="default" size="100%">June 2024</style></date></pub-dates></dates><volume><style face="normal" font="default" size="100%">16</style></volume><pages><style face="normal" font="default" size="100%">687-690</style></pages><language><style face="normal" font="default" size="100%">eng</style></language><abstract><style face="normal" font="default" size="100%">&lt;p class=&quot;rtejustify&quot;&gt;Simblefaron is one of the most challenging complications in the late stages of an alkali burn. Symblepharon characteristically resembles connective tissue or bands that protrude from the eyelid's interior surface (palpebral conjunctiva) to the surface of the eyeball (bulbar conjunctiva). This literature review was conducted to see the molecular mechanism of symblepharon formation. Matrix metalloproteinase (MMP- 9), transforming growth factor (TGF-β), and Fibroblast played a significant part in the healing of conjunctival wounds. MMP-9, TGF-β, and fibroblast overexpressed are suspected to cause excessive inflammation and fibrosis, which results in symblepharon. By knowing this, it is hoped that it can become a basis for developing appropriate management for the occurrence of simblepharon.&lt;/p&gt;
</style></abstract><issue><style face="normal" font="default" size="100%">3</style></issue><work-type><style face="normal" font="default" size="100%">687-690</style></work-type><section><style face="normal" font="default" size="100%">687</style></section><auth-address><style face="normal" font="default" size="100%">&lt;p&gt;Dian Mayangsari&lt;sup&gt;1&lt;/sup&gt;*, Lukisiari Agustini&lt;sup&gt;1&lt;/sup&gt;, Susy Fatmariyanti&lt;sup&gt;1&lt;/sup&gt;, Ridholia&lt;sup&gt;2&lt;/sup&gt;, Pudji Lestari&lt;sup&gt;3&lt;/sup&gt;&lt;/p&gt;

&lt;p&gt;&lt;sup&gt;1&lt;/sup&gt;Department of Ophthalmology, Faculty of Medicine, Universitas Airlangga/Dr. Soetomo General Academic Hospital, Surabaya, East Java, INDONESIA.&lt;/p&gt;

&lt;p&gt;&lt;sup&gt;2&lt;/sup&gt;Department of Anatomical Pathology, Faculty of Medicine, Universitas Airlangga/ Dr. Soetomo General Academic Hospital, Surabaya, East Java, INDONESIA.&lt;/p&gt;

&lt;p&gt;&lt;sup&gt;3&lt;/sup&gt;Department of IKM-KP, Faculty of Medicine, Universitas Airlangga/Dr. Soetomo General Academic Hospital, Surabaya, East Java, INDONESIA.&lt;/p&gt;
</style></auth-address></record><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Henu Hadiyantama</style></author><author><style face="normal" font="default" size="100%">Lukisiari Agustini</style></author><author><style face="normal" font="default" size="100%">Sutjipto</style></author><author><style face="normal" font="default" size="100%">Evelyn Komaratih</style></author><author><style face="normal" font="default" size="100%">Ismi Zuhria</style></author><author><style face="normal" font="default" size="100%">Pudji Lestari</style></author><author><style face="normal" font="default" size="100%">Ridholia</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">The Role of α-SMA, Type 1 Collagen, and Myofibroblasts in Cicatrizing Conjunctivitis by Alkali Chemical Trauma</style></title><secondary-title><style face="normal" font="default" size="100%">Pharmacognosy Journal</style></secondary-title></titles><keywords><keyword><style  face="normal" font="default" size="100%">Cicatrizing conjunctivitis</style></keyword><keyword><style  face="normal" font="default" size="100%">Myofibroblasts</style></keyword><keyword><style  face="normal" font="default" size="100%">Type 1 collagen</style></keyword><keyword><style  face="normal" font="default" size="100%">α -SMA</style></keyword></keywords><dates><year><style  face="normal" font="default" size="100%">2024</style></year><pub-dates><date><style  face="normal" font="default" size="100%">May 2024</style></date></pub-dates></dates><volume><style face="normal" font="default" size="100%">16</style></volume><pages><style face="normal" font="default" size="100%">591-596</style></pages><language><style face="normal" font="default" size="100%">eng</style></language><abstract><style face="normal" font="default" size="100%">&lt;p class=&quot;rtejustify&quot;&gt;&lt;strong&gt;Introduction: &lt;/strong&gt;Chemical trauma to the eye is a serious condition in the field of ophthalmology and a leading factor contributing to global blindness. Cicatrizing conjunctivitis (CC) is a term used to describe conditions marked by inflammation and the formation of scars on the conjunctiva. CC can have various causes, with one of them being chemical injury to the eye. The development of CC involves the participation of several cytokines and cells, such as α-SMA, Type 1 collagen, and Myofibroblasts. Myofibroblasts have the ability to contract through the utilization of diverse cytoskeletal proteins, which are commonly present in smooth muscle cells, including α-SMA. Actin filaments contribute to mechanically supporting cells, defining cell morphology, and facilitating cell mobility. Actin, in conjunction with myosin, participates in the muscle contraction process within muscle cells. Subsequently, type 1 collagen contributes to the healing of conjunctival wounds by providing a tensile force that aids in the closure of such wounds. As a significant constituent of the extracellular matrix, type 1 collagen plays a crucial role in maintaining the integrity of tissues.&lt;/p&gt;
</style></abstract><issue><style face="normal" font="default" size="100%">3</style></issue><work-type><style face="normal" font="default" size="100%">Research Article</style></work-type><section><style face="normal" font="default" size="100%">591</style></section><auth-address><style face="normal" font="default" size="100%">&lt;p class=&quot;rtejustify&quot;&gt;&lt;strong&gt;Henu Hadiyantama&lt;sup&gt;1&lt;/sup&gt;, Lukisiari Agustini&lt;sup&gt;1*&lt;/sup&gt;, Sutjipto&lt;sup&gt;1&lt;/sup&gt;, Evelyn Komaratih&lt;sup&gt;1&lt;/sup&gt;, Ismi Zuhria&lt;sup&gt;1&lt;/sup&gt;, Pudji Lestari&lt;sup&gt;2&lt;/sup&gt;, Ridholia&lt;sup&gt;3&lt;/sup&gt;&lt;/strong&gt;&lt;/p&gt;

&lt;p class=&quot;rtejustify&quot;&gt;&lt;sup&gt;1&lt;/sup&gt;Department of Ophthalmology, Faculty of Medicine, Universitas Airlangga/Dr. Soetomo General Academic Hospital, Surabaya, INDONESIA.&lt;/p&gt;

&lt;p class=&quot;rtejustify&quot;&gt;&lt;sup&gt;2&lt;/sup&gt;Department of Public Health, Faculty of Medicine, Universitas Airlangga, Surabaya, INDONESIA. 3Department of Pathology Anatomy, Faculty of Medicine/Dr. Soetomo General Academic Hospital, Universitas Airlangga, Surabaya, INDONESIA.&lt;/p&gt;
</style></auth-address></record></records></xml>